In atheroembolic kidney disease, numerous small pieces of fatty material (atheroemboli) travel from arteries above the kidneys to clog the smallest branches of the renal arteries, causing the kidneys to fail.
Tiny pieces of hard fatty material adhering to a hardened (atherosclerotic) blood vessel wall, usually the aorta, break off and travel through the bloodstream, becoming emboli (atheroemboli). Some emboli travel to the smallest renal arteries, blocking parts of the kidney's blood supply. Usually, this process affects both kidneys about equally and at the same time.
The fatty material may break off spontaneously when there is severe atherosclerosis of the aorta. It more commonly occurs as a complication of surgery or angioplasty or of imaging procedures that involve the aorta, such as arteriography, when pieces of fatty material adhering to the walls of the aorta are unintentionally broken off. Atheroembolic kidney disease is much more common in older people.
Atheroembolic kidney disease usually causes acute or slowly progressive inability of the kidneys to filter waste products from the blood (kidney failure). If the blockage of arteries results from a surgical or imaging procedure involving the aorta, the kidneys often fail suddenly. Urine production is often decreased.
As the duration and severity of kidney failure increase, various symptoms may appear, beginning with fatigue, nausea, loss of appetite, itching, and difficulty concentrating. The symptoms reflect disturbances in the muscles, brain, nerves, heart, digestive tract, and skin that result from kidney failure.
Atheroemboli may cause symptoms in other organs. If atheroemboli travel to the arms or legs, such symptoms as blue toes or a lacy purplish discoloration of the skin and even gangrene may result. Pieces of atheroemboli that travel to an eye may cause sudden blindness.
Doctors suspect atheroembolic kidney disease in a person who has a decline in kidney function after a procedure that involved the aorta. Blood or urine tests can show that kidney function is declining. A kidney biopsy is the best way for doctors to confirm the diagnosis of atheroembolic kidney disease but is usually not necessary. A tissue sample examined with a microscope shows characteristic evidence of fatty material in the smallest arteries. Examination of skin or muscle specimens may also help to establish the diagnosis. Sometimes echocardiography of the aorta is needed to determine the source of the emboli.
Prognosis and Treatment
In the past, people with atheroembolic kidney disease tended to die within weeks or months. However, more recently, treatment has improved. Most people live at least a year. About half live 4 years or more.
Sometimes the source of the emboli can be treated so new emboli do not form, but no direct treatment to remove existing kidney atheroemboli is available. The treatment is to support the person as well as possible. For example, high blood pressure is treated. Dialysis may be needed during kidney failure, but sometimes the kidneys eventually resume functioning.
Last full review/revision June 2014 by Zhiwei Zhang, MD